TALLINN, ESTONIA/RIGA, LATVIA – April 21, 2026 – DrugCards OÜ (brand name “DrugCard”), a leading developer of AI agents for drug safety departments, today announced the successful acquisition of 100% of the shares of SIA OOM, a specialized pharmacovigilance service provider based in Riga, Latvia.
This strategic acquisition marks DrugCard’ first M&A transaction and signifies a pivotal shift from a dedicated SaaS platform to an integrated, end-to-end pharmacovigilance infrastructure provider in the European Union.
SIA OOM is a well-established player in the Baltic region, providing critical local pharmacovigilance services, including Local QPPV representation, medical literature monitoring, and regulatory reporting in Latvia and Lithuania. The company holds a robust portfolio of over 20 long-term contracts with global pharmaceutical leaders.
Strategic Rationale and Market Impact
The integration of SIA OOM into the DrugCard ecosystem provides:
- Direct Baltic Presence: Official operational infrastructure and physical presence within the Baltic regulatory framework, enhancing the company’s ability to navigate local compliance nuances.
- Service Continuity: Ensuring seamless delivery of local PV requirements for existing international clients and partners, maintaining the high standards of safety monitoring SIA OOM is known for.
- Technological Synergy: Migrating established service workflows onto the DrugCards automated platform. This allows for real-time monitoring and data processing, significantly reducing manual overhead while increasing the reliability of safety reports for current SIA OOM partners.
- Geographical Scaling: This acquisition serves as a launchpad for further expansion into the Central, Eastern European (CEE) and DACH markets, combining local ground-level expertise with scalable digital solutions.
Bridging the Gap Between Technology and Compliance
In an era of increasing regulatory pressure and data complexity, the “Hybrid” model addresses a critical market need. By acting as both a technology vendor and a service provider, DrugCard can offer a unique feedback loop: the software is refined by real-world PV practice, and the services are optimized by cutting-edge automation.
“The acquisition of SIA OOM is a logical step in our mission to automate and simplify pharmacovigilance compliance across Europe,” said Dmytro Horilyk, CEO of DrugCard. “By combining SIA OOM’s deep local expertise with our proprietary automation technology, we are building a more resilient and scalable PV infrastructure for pharmaceutical companies operating in Central and Eastern Europe. We aren’t just providing a tool; we are providing a verified, automated pathway to compliance.”
Commitment to Continuity and Quality
DrugCard emphasizes that for all current clients and partners of SIA OOM, the transition will be seamless. All existing contracts, local representation roles, and the core expert team remain unchanged. Clients will gain the added benefit of early access to DrugCard’ advanced technological capabilities, providing them with enhanced data transparency and faster processing times.
Future Outlook
This acquisition is part of a broader strategy to establish DrugCard as the primary pharmacovigilance partner in Europe. The company plans to continue its growth through both technological innovation and strategic acquisitions of local PV agencies, creating a unified, tech-enabled safety network.
About DrugCards OÜ
DrugCard is a health-tech company specializing in AI agents for pharmacovigilance processes. Its flagship SaaS platform helps pharmaceutical companies and CROs ensure GVP compliance through enrolling autonomous AI agents to speed up routine processes like medical literature monitoring and data processing, reducing human error and operational costs.
About SIA OOM
SIA OOM is a boutique pharmacovigilance agency based in Riga, providing essential local safety services, regulatory support, and QPPV representation in the Baltic states.
